Induction of durable remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab

Arthritis & Rheumatism, 04/27/2012

This first report of the use and clinical efficacy of eculizumab, an inhibitor of complement activation, in the therapy of catastrophic antiphospholipid syndrome (CAPS) demonstrates both the importance of complement (specifically terminal complement components) in the pathogenesis of CAPS and the therapeutic benefit of complement inactivation.

Print Article Summary Cat 2 CME Report